IDx avoids telehealth designation to improve market access

October 15, 2018 | Case Study

The U.S. Center for Medicaid and Medicare Services (CMS) sets the standard of reimbursement rates for medical services. Despite evolving standards of care across the telehealth space, the CMS routinely does not reimburse for telehealth, greatly limiting adoption. IDx, a company that develops tools to diagnose diabetic retinopathy without the aid of a trained specialist, has decided to forego the telehealth nomenclature for this reason, instead designating itself as a specialist health company. IDx is taking a unique approach in acquiring a U.S. FDA designation as specialty care despite telehealth applications to circumvent the lack of reimbursement and increase adoption by doctors.